Bio
Liz Rolla is a Vice President of Product with over a decade of experience across healthcare IT, market access intelligence, and pharmaceutical marketing. Her deep roots in pharma — from product launches and patient support programs to market access strategy — give her a unique lens for identifying where AI can drive meaningful impact across the drug commercialization lifecycle.
What can pharma teams do now that was not possible two years ago?
AI is transforming how pharmaceutical companies connect the right therapy to the right patient at the right time — from predicting payer behavior and optimizing formulary strategies, to identifying patients at risk of abandoning treatment before it happens. On the commercial side, AI enables hyper-personalized HCP engagement that moves far beyond traditional detailing, delivering the right message, on the right channel, at the precise moment it matters. Together, these capabilities don’t just improve efficiency — they create a connected commercialization ecosystem that drives better access, stronger adherence, and ultimately, better patient outcomes.
How can AI accelerate the journey from pipeline to patient?
The path from a promising drug candidate to a patient’s hands has traditionally taken 10–15 years and cost billions — AI is compressing that timeline at every stage. By connecting the historically fragmented journey from pipeline to patient, AI is turning disconnected steps into an intelligent, adaptive system with one goal: getting the right therapy to the right patient, faster.